BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, Lecomte JM, Schwartz JC; HARMONY III study group. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep 2019;42:zsz174. [PMID: 31529094 DOI: 10.1093/sleep/zsz174] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhou X, Zhou B, Li Z, Lu Q, Li S, Pu Z, Luo F. Gender differences of clinical and polysomnographic findings with obstructive sleep apnea syndrome. Sci Rep 2021;11:5938. [PMID: 33723369 DOI: 10.1038/s41598-021-85558-y] [Reference Citation Analysis]
2 Yoshikawa T, Nakamura T, Yanai K. Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness. Br J Pharmacol 2021;178:750-69. [PMID: 32744724 DOI: 10.1111/bph.15220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Harwell V, Fasinu PS. Pitolisant and Other Histamine-3 Receptor Antagonists-An Update on Therapeutic Potentials and Clinical Prospects. Medicines (Basel) 2020;7:E55. [PMID: 32882898 DOI: 10.3390/medicines7090055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Ishikawa O, Hahn S, Greenberg H; Northwell Sleep Disorders Centre, Division of Pulmonary, Critical Care and Sleep Medicine, Donald and Barbara Zucker School of Medicine, Hofstra-Northwell, Northwell Health, NY, USA, Northwell Sleep Disorders Centre, Division of Pulmonary, Critical Care and Sleep Medicine, Donald and Barbara Zucker School of Medicine, Hofstra-Northwell, Northwell Health, NY, USA, Northwell Sleep Disorders Centre, Division of Pulmonary, Critical Care and Sleep Medicine, Donald and Barbara Zucker School of Medicine, Hofstra-Northwell, Northwell Health, NY, USA. Pharmacologic Therapy for Narcolepsy. Neurology 2022;18:68. [DOI: 10.17925/usn.2022.18.1.68] [Reference Citation Analysis]
5 Hanin C, Arnulf I, Maranci JB, Lecendreux M, Levinson DF, Cohen D, Laurent-Levinson C. Narcolepsy and psychosis: A systematic review. Acta Psychiatr Scand 2021;144:28-41. [PMID: 33779983 DOI: 10.1111/acps.13300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Guevarra JT, Hiensch R, Varga AW, Rapoport DM. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility. Nat Sci Sleep 2020;12:709-19. [PMID: 33117007 DOI: 10.2147/NSS.S264140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord 2019;12:1756286419875622. [PMID: 31632459 DOI: 10.1177/1756286419875622] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
8 Imeri F, Stepanovska Tanturovska B, Zivkovic A, Enzmann G, Schwalm S, Pfeilschifter J, Homann T, Kleuser B, Engelhardt B, Stark H, Huwiler A. Novel compounds with dual S1P receptor agonist and histamine H3 receptor antagonist activities act protective in a mouse model of multiple sclerosis. Neuropharmacology 2021;186:108464. [PMID: 33460688 DOI: 10.1016/j.neuropharm.2021.108464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 de Biase S, Pellitteri G, Gigli GL, Valente M. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother 2021;22:155-62. [PMID: 32941089 DOI: 10.1080/14656566.2020.1817387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Pépin JL, Georgiev O, Tiholov R, Attali V, Verbraecken J, Buyse B, Partinen M, Fietze I, Belev G, Dokic D, Tamisier R, Lévy P, Lecomte I, Lecomte JM, Schwartz JC, Dauvilliers Y; HAROSA I Study Group. Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial. Chest 2021;159:1598-609. [PMID: 33121980 DOI: 10.1016/j.chest.2020.09.281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Dauvilliers Y, Verbraecken J, Partinen M, Hedner J, Saaresranta T, Georgiev O, Tiholov R, Lecomte I, Tamisier R, Lévy P, Scart-Gres C, Lecomte JM, Schwartz JC, Pépin JL; HAROSA II Study Group collaborators. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial. Am J Respir Crit Care Med 2020;201:1135-45. [PMID: 31917607 DOI: 10.1164/rccm.201907-1284OC] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
12 Bassetti CLA, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, Dolenc-Groselj L, Jennum P, Khatami R, Manconi M, Mayer G, Partinen M, Pollmächer T, Reading P, Santamaria J, Sonka K, Dauvilliers Y, Lammers GJ. European guideline and expert statements on the management of narcolepsy in adults and children. J Sleep Res 2021;:e13387. [PMID: 34173288 DOI: 10.1111/jsr.13387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rusjan P, Sabioni P, Di Ciano P, Mansouri E, Boileau I, Laveillé A, Capet M, Duvauchelle T, Schwartz JC, Robert P, Le Foll B. Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET. Br J Pharmacol 2020;177:3464-72. [PMID: 32293706 DOI: 10.1111/bph.15067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Germundson DL, Vendsel LP, Nagamoto-Combs K. Region-specific regulation of central histaminergic H3 receptor expression in a mouse model of cow's milk allergy. Brain Res 2020;1749:147148. [PMID: 33035498 DOI: 10.1016/j.brainres.2020.147148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lamb YN. Pitolisant: A Review in Narcolepsy with or without Cataplexy. CNS Drugs 2020;34:207-18. [PMID: 31997137 DOI: 10.1007/s40263-020-00703-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
16 Li S, Yang J. Pitolisant for treating patients with narcolepsy. Expert Review of Clinical Pharmacology 2020;13:79-84. [DOI: 10.1080/17512433.2020.1714435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Parmar A, Murray BJ, Narang I. Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy. Curr Neurol Neurosci Rep 2020;20:38. [PMID: 32651734 DOI: 10.1007/s11910-020-01057-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Meskill GJ, Kallweit U, Zarycranski D, Caussé C, Finance O, Ligneau X, Davis CW. Pitolisant for the treatment of cataplexy in adults with narcolepsy. Expert Opinion on Orphan Drugs. [DOI: 10.1080/21678707.2021.2022472] [Reference Citation Analysis]
19 Carthy E, Ellender T. Histamine, Neuroinflammation and Neurodevelopment: A Review. Front Neurosci 2021;15:680214. [PMID: 34335160 DOI: 10.3389/fnins.2021.680214] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Bolin K, Niska PÅ, Pirhonen L, Wasling P, Landtblom AM. The cost utility of pitolisant as narcolepsy treatment. Acta Neurol Scand 2020;141:301-10. [PMID: 31838740 DOI: 10.1111/ane.13202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Cheng L, Liu J, Chen Z. The Histaminergic System in Neuropsychiatric Disorders. Biomolecules 2021;11:1345. [PMID: 34572558 DOI: 10.3390/biom11091345] [Reference Citation Analysis]
22 . Pitolisant (Wakix) for Narcolepsy. JAMA 2021;326:1060-1. [PMID: 34546302 DOI: 10.1001/jama.2021.1349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Ainge-Allen HW, Yee BJ, Ip MSM. Contemporary Concise Review 2020: Sleep. Respirology 2021;26:700-6. [PMID: 34018277 DOI: 10.1111/resp.14084] [Reference Citation Analysis]
24 Bassetti CLA, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, Dolenc-Groselj L, Jennum P, Khatami R, Manconi M, Mayer G, Partinen M, Pollmächer T, Reading P, Santamaria J, Sonka K, Dauvilliers Y, Lammers GJ. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol 2021;28:2815-30. [PMID: 34173695 DOI: 10.1111/ene.14888] [Reference Citation Analysis]
25 Rosenthal L, Thorpy MJ, Nevsimalova S, Mayer G, Han F, Dauvilliers Y. 2018 worldwide survey of health-care providers caring for patients with narcolepsy: WSS narcolepsy task force. Sleep Med 2021;82:23-8. [PMID: 33873103 DOI: 10.1016/j.sleep.2021.03.014] [Reference Citation Analysis]
26 Akpa B, Lee K. Update on Novel Medications to Treat Narcolepsy. Curr Sleep Medicine Rep 2020;6:189-97. [DOI: 10.1007/s40675-020-00178-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Vázquez-vázquez H, Gonzalez-sandoval C, Vega AV, Arias-montaño J, Barral J. Histamine H3 Receptor Activation Modulates Glutamate Release in the Corticostriatal Synapse by Acting at CaV2.1 (P/Q-Type) Calcium Channels and GIRK (KIR3) Potassium Channels. Cell Mol Neurobiol. [DOI: 10.1007/s10571-020-00980-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Laurino A, Gencarelli M, Raimondi L. The 3-iodothyronamine (T1AM) and the 3-iodothyroacetic acid (TA1) indicate a novel connection with the histamine system for neuroprotection. Eur J Pharmacol 2021;912:174606. [PMID: 34717926 DOI: 10.1016/j.ejphar.2021.174606] [Reference Citation Analysis]
29 Weaver TE, Pepin JL, Schwab R, Shapiro C, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Bron M, Chandler P, Lee L, Malhotra A. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. J Clin Sleep Med 2021;17:1995-2007. [PMID: 34606437 DOI: 10.5664/jcsm.9384] [Reference Citation Analysis]
30 Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020;34:9-27. [PMID: 31953791 DOI: 10.1007/s40263-019-00689-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
31 Jennum PJ, Plazzi G, Silvani A, Surkin LA, Dauvilliers Y. Cardiovascular disorders in narcolepsy: Review of associations and determinants. Sleep Med Rev 2021;58:101440. [PMID: 33582582 DOI: 10.1016/j.smrv.2021.101440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Kimura Y, Takahata K, Shimazaki T, Kitamura S, Seki C, Ikoma Y, Ichise M, Kawamura K, Yamada M, Zhang MR, Higuchi M, Nishino I, Suhara T. Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457. Eur J Nucl Med Mol Imaging 2021. [PMID: 34651222 DOI: 10.1007/s00259-021-05571-1] [Reference Citation Analysis]
33 Sarfraz N, Okuampa D, Hansen H, Alvarez M, Cornett EM, Kakazu J, Kaye AM, Kaye AD. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Health Psychology Research 2022;10. [DOI: 10.52965/001c.34222] [Reference Citation Analysis]
34 Yuan S, Yu B, Liu H. New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry 2020;205:112667. [DOI: 10.1016/j.ejmech.2020.112667] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]